NCT05038982View on ClinicalTrials.gov

Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

July 11, 2022

Study Completion Date

July 11, 2022

Conditions
Prurigo NodularisPruritusChronic PruritusChronic PrurigoSkin Diseases
Interventions
DRUG

Abrocitinib

During the study period, subjects will take one Abrocitinib 200 mg tablet once daily orally. Subjects will be directed to take doses of Abrocitinib at approximately the same time of day.

Trial Locations (1)

21205

Johns Hopkins Outpatient Center, Baltimore

Sponsors

Collaborators (2)

Duke University
Pfizer
All Listed Sponsors
collaborator

Duke University

OTHER

collaborator

Pfizer

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT05038982 - Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin | Biotech Hunter | Biotech Hunter